Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Prostatic Neoplasms 2 Weight Loss 1 Urinary Bladder Neoplasms 1 Sleep Apnea Syndromes 1 Sezary Syndrome 1 Sarcoma 1 Recurrence 1 Overweight 1 Obesity, Morbid 1 Obesity 1 Non-Muscle Invasive Bladder Neoplasms 1 Neoplasm Metastasis 1 Mycosis Fungoides 1 Multiple Myeloma 1 Lymphoma, T-Cell, Cutaneous 1 Lung Neoplasms 1 Hypertension 1 Hyperlipidemias 1 Gastroesophageal Reflux 1 Eczema 1 Disease 1 Digestive System Diseases 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus 1 Dermatitis, Atopic 1 Collagen Diseases 1 Adenocarcinoma 1

Interventions

Doxorubicin 26 pembrolizumab 24 Radiotherapy 20 Cyclophosphamide 18 Magnetic Resonance Spectroscopy 17 Specimen Handling 14 Nivolumab 14 Gemcitabine 13 Ifosfamide 12 Surgical Procedures, Operative 11 Biopsy 11 Radiation 10 X-Rays 8 Temozolomide 8 Ipilimumab 8 pazopanib 7 fludarabine 7 cabozantinib 7 Irinotecan 7 tazemetostat 6 liposomal doxorubicin 6 Trabectedin 6 Surveys and Questionnaires 6 Phantoms, Imaging 6 Blood Specimen Collection 6 olaparib 5 eribulin 5 atezolizumab 5 anlotinib 5 Vincristine 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Sarcoma × Urine Specimen Collection × 1 year × Clear all

NCT06482957 2025-09-19

CAUSAL

Vanderbilt-Ingram Cancer Center

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡